mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis
The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells’ survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mT...
Saved in:
Published in | Medical oncology (Northwood, London, England) Vol. 27; no. 4; pp. 1239 - 1245 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Boston
Springer US
01.12.2010
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells’ survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients’ prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan–Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy. |
---|---|
AbstractList | The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients' prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.[PUBLICATION ABSTRACT] The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients' prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy. The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients' prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells ( greater than or equal to 90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy. The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients' prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients' prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy. |
Author | Zhou, Quan Zhao, Jiali Deng, Zhansheng Long, Haitao Zhang, Shaoxian Zhu, Yong |
Author_xml | – sequence: 1 givenname: Quan surname: Zhou fullname: Zhou, Quan organization: Department of Orthopaedics, Huai’an Hospital, Xuzhou Medical College – sequence: 2 givenname: Zhansheng surname: Deng fullname: Deng, Zhansheng email: wuque1@hotmail.com organization: Department of Spinal Surgery, Xiangya Hospital, Central South University – sequence: 3 givenname: Yong surname: Zhu fullname: Zhu, Yong organization: Department of Orthopaedics, Xiangya Hospital, Central South University – sequence: 4 givenname: Haitao surname: Long fullname: Long, Haitao organization: Department of Orthopaedics, Xiangya Hospital, Central South University – sequence: 5 givenname: Shaoxian surname: Zhang fullname: Zhang, Shaoxian organization: Department of Orthopaedics, Huai’an Hospital, Xuzhou Medical College – sequence: 6 givenname: Jiali surname: Zhao fullname: Zhao, Jiali organization: Department of Orthopaedics, Huai’an Hospital, Xuzhou Medical College |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19936974$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kdtqFTEUhoNU7EEfwBsZvNGbsTlMMrMupXjCQsFW8C5kMpltykyyzcpQ9p2v4ev5JGbcVaFgrxLI960V_v-YHIQYHCFPGX3FKG1PkXEqeE0p1CCUrHcPyBGTEmom2JeDcheyralU9JAcI15Typnk8IgcMig8tM0R8fPVxafTbUsv1cfq0m-CmaqcTMBhsdnHUG1N_npjdpWNISffL9lhlWMVMbuIJtk4m2qb4iY5xJU3YVgd70LGn99__H4LET0-Jg9HM6F7cnuekM9v31ydva_PL959OHt9XttGQa47agcwzdjzxraCWzEAgLMwCjoaaZhsuQGjetV3Y0-dE1wMDXSKKesodJ04IS_2c8vmb4vDrGeP1k2TCS4uqDvGSy6SreTLe0lGQTSq5R0U9Pkd9DouqYSFGjgrZfBmhZ7dQks_u0Fvk59N2uk_aReg3QM2RcTkRm19NmvMJXI_lYV67VXve9WlV732qnfFZHfMv8PvcfjewcKGjUv__vx_6ReU67be |
CODEN | MONCEZ |
CitedBy_id | crossref_primary_10_1016_j_canlet_2016_12_012 crossref_primary_10_1002_ijc_28933 crossref_primary_10_1073_pnas_1419260111 crossref_primary_10_1016_j_biopha_2017_08_116 crossref_primary_10_1093_annonc_mdx709 crossref_primary_10_3389_fonc_2019_00390 crossref_primary_10_1038_tpj_2016_45 crossref_primary_10_1158_1078_0432_CCR_12_2293 crossref_primary_10_3389_pore_2022_1610231 crossref_primary_10_1002_cncr_26617 crossref_primary_10_1158_1535_7163_MCT_19_0689 crossref_primary_10_1016_j_abb_2013_04_001 crossref_primary_10_1093_annonc_mdx536 crossref_primary_10_1016_j_jaad_2013_04_027 crossref_primary_10_1155_2013_480713 crossref_primary_10_3390_cancers12113097 crossref_primary_10_1038_s41419_022_05401_8 crossref_primary_10_1158_1078_0432_CCR_21_0315 crossref_primary_10_2147_OTT_S249477 crossref_primary_10_1002_pbc_28072 crossref_primary_10_18632_oncotarget_10389 crossref_primary_10_1155_2011_460650 crossref_primary_10_1158_0008_5472_CAN_10_0578 crossref_primary_10_1517_14728214_2015_1051965 crossref_primary_10_1016_j_path_2011_07_015 crossref_primary_10_1136_jclinpath_2020_206505 crossref_primary_10_3390_cells9040968 crossref_primary_10_18632_genesandcancer_91 crossref_primary_10_3390_ijms17040506 crossref_primary_10_1186_s41016_019_0162_y crossref_primary_10_1186_s12935_020_01342_4 crossref_primary_10_3389_fendo_2015_00074 crossref_primary_10_1002_cbin_10075 crossref_primary_10_1038_s41419_023_05910_0 crossref_primary_10_3892_ijmm_2024_5393 crossref_primary_10_1038_nrendo_2017_16 crossref_primary_10_3390_cells10051240 crossref_primary_10_1073_pnas_1420596111 crossref_primary_10_1038_srep09604 crossref_primary_10_31083_j_fbl2704122 crossref_primary_10_3892_ol_2014_1935 crossref_primary_10_3390_cancers14143503 crossref_primary_10_1016_j_bbrc_2018_02_050 crossref_primary_10_1016_j_annpat_2011_10_009 crossref_primary_10_1038_s41420_022_00838_4 crossref_primary_10_1517_21678707_2014_917951 crossref_primary_10_3892_or_2016_4922 crossref_primary_10_1186_s41065_021_00174_0 crossref_primary_10_1177_03009858231207021 crossref_primary_10_1186_s13018_018_0860_8 |
Cites_doi | 10.1038/sj.onc.1209691 10.1002/cncr.22677 10.1016/j.ctrv.2006.05.005 10.1016/j.ceb.2005.02.008 10.1038/nm1052 10.1158/1078-0432.CCR-04-0969 10.1267/ahc.06005 10.1016/j.canlet.2007.01.026 10.1158/1078-0432.CCR-05-1654 10.1126/science.1066015 10.1038/sj.bjc.6600201 10.1002/ijc.21932 10.1093/jnci/92.15.1252 10.1042/BST0320393 10.1073/pnas.171301998 10.1038/ng1494 10.1007/BF00625047 10.1080/00313020802436808 10.1016/j.critrevonc.2004.09.009 10.1586/14737140.6.7.1075 10.1186/1477-7800-3-7 10.1186/1471-2164-9-348 10.1158/0008-5472.CAN-05-3830 10.1016/j.molmed.2005.06.007 10.1097/01.cad.0000173476.67239.3b 10.1097/00003086-198011000-00013 10.1016/j.suronc.2009.09.002 10.1042/bst0320393 |
ContentType | Journal Article |
Copyright | Springer Science+Business Media, LLC 2009 Springer Science+Business Media, LLC 2010 |
Copyright_xml | – notice: Springer Science+Business Media, LLC 2009 – notice: Springer Science+Business Media, LLC 2010 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7QP 7X8 |
DOI | 10.1007/s12032-009-9365-y |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1559-131X |
EndPage | 1245 |
ExternalDocumentID | 2584253511 19936974 10_1007_s12032_009_9365_y |
Genre | Journal Article Feature |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 2.D 203 28- 29M 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 3V. 4.4 406 408 40E 53G 5GY 5RE 5VS 6NX 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABIPD ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABUWG ABWNU ABXPI ACAOD ACCUX ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACUDM ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI H13 HF~ HG6 HMCUK HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ IMOTQ IWAJR IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV LLZTM M1P M4Y MA- N2Q N9A NDZJH NF0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OVD P19 P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 PZZ Q2X QOK QOR QOS R89 R9I RHV RIG RNI ROL RPX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 YLTOR Z7U Z82 Z87 Z8O Z8V Z91 ZMTXR ZOVNA ZXP ~A9 ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7QP 7X8 |
ID | FETCH-LOGICAL-c469t-80cd9a4fb24c732c3d999ec9f30fa5a1572a9a6b6b8fb0ee323d498616ce09883 |
IEDL.DBID | U2A |
ISSN | 1357-0560 1559-131X |
IngestDate | Tue Aug 05 11:04:55 EDT 2025 Thu Aug 07 15:09:46 EDT 2025 Fri Aug 15 22:51:29 EDT 2025 Mon Jul 21 05:55:49 EDT 2025 Thu Apr 24 23:06:26 EDT 2025 Tue Jul 01 01:49:02 EDT 2025 Fri Feb 21 02:33:48 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Prognosis p70 S6 kinase Osteosarcoma Clinical pathology Mammalian target of rapamycin |
Language | English |
License | http://www.springer.com/tdm |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c469t-80cd9a4fb24c732c3d999ec9f30fa5a1572a9a6b6b8fb0ee323d498616ce09883 |
Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-2 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 19936974 |
PQID | 921100249 |
PQPubID | 30753 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_812135518 proquest_miscellaneous_1093467289 proquest_journals_921100249 pubmed_primary_19936974 crossref_citationtrail_10_1007_s12032_009_9365_y crossref_primary_10_1007_s12032_009_9365_y springer_journals_10_1007_s12032_009_9365_y |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2010-12-01 |
PublicationDateYYYYMMDD | 2010-12-01 |
PublicationDate_xml | – month: 12 year: 2010 text: 2010-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Boston |
PublicationPlace_xml | – name: Boston – name: United States – name: Middlesex |
PublicationTitle | Medical oncology (Northwood, London, England) |
PublicationTitleAbbrev | Med Oncol |
PublicationTitleAlternate | Med Oncol |
PublicationYear | 2010 |
Publisher | Springer US Springer Nature B.V |
Publisher_xml | – name: Springer US – name: Springer Nature B.V |
References | Kaya, Wada, Kawaguchi (CR19) 2002; 86 Majumder (CR24) 2004; 10 Inoki, Corradetti, Guan (CR7) 2005; 37 Liu (CR12) 2006; 25 Harada, Andersen, Mann, Terada, Korsmeyer (CR26) 2001; 98 Heinonen, Nieminen, Saarela, Kallioniemi, Klefström, Hautaniemi (CR14) 2008; 9 Guertin, Sabatini (CR8) 2005; 11 Fang, Vilella-Bach, Bachmann, Flanigan, Chen (CR22) 2001; 294 Couch (CR11) 1999; 59 Hou, Xue, Lu, Fan, Tian, Xue (CR28) 2007; 253 Pantuck, Seligson, Klatte (CR17) 2007; 109 Mungamuri, Yang, Thor, Somasundaram (CR23) 2006; 66 Enneking, Spanier, Goodman (CR15) 1980; 153 Morgensztern, McLeod (CR25) 2005; 16 Ek, Ojaimi, Kitagawa, Choong (CR3) 2006; 3 Chou, Gorlick (CR2) 2006; 6 Kreuter, Bieker, Bielack (CR18) 2004; 10 CR5 Workman (CR20) 2004; 32 Salzer-Kuntschik, Delling, Beron, Sigmund (CR16) 1983; 106 Osaka, Suzuki, Osaka, Yoshida, Sugita, Asami (CR6) 2006; 39 Longhi, Errani, De Paolis (CR1) 2006; 32 Granville, Memmot, Gills, Dennis (CR21) 2006; 12 Beevers, Li, Liu, Huang (CR27) 2006; 119 Law (CR10) 2005; 56 Huang, Zhu, Lu, Lian, Wang, Yang (CR4) 2009; 41 Bärlund (CR13) 2000; 92 Martin, Hall (CR9) 2005; 17 SK Mungamuri (9365_CR23) 2006; 66 K Inoki (9365_CR7) 2005; 37 DA Guertin (9365_CR8) 2005; 11 M Salzer-Kuntschik (9365_CR16) 1983; 106 FJ Couch (9365_CR11) 1999; 59 AJ Pantuck (9365_CR17) 2007; 109 BK Law (9365_CR10) 2005; 56 G Hou (9365_CR28) 2007; 253 M Kaya (9365_CR19) 2002; 86 ETH Ek (9365_CR3) 2006; 3 L Liu (9365_CR12) 2006; 25 CA Granville (9365_CR21) 2006; 12 M Bärlund (9365_CR13) 2000; 92 CS Beevers (9365_CR27) 2006; 119 P Workman (9365_CR20) 2004; 32 PK Majumder (9365_CR24) 2004; 10 DE Martin (9365_CR9) 2005; 17 WF Enneking (9365_CR15) 1980; 153 AJ Chou (9365_CR2) 2006; 6 D Morgensztern (9365_CR25) 2005; 16 A Longhi (9365_CR1) 2006; 32 Y Fang (9365_CR22) 2001; 294 H Harada (9365_CR26) 2001; 98 H Heinonen (9365_CR14) 2008; 9 E Osaka (9365_CR6) 2006; 39 M Kreuter (9365_CR18) 2004; 10 9365_CR5 J Huang (9365_CR4) 2009; 41 11729323 - Science. 2001 Nov 30;294(5548):1942-5 15156201 - Nat Med. 2004 Jun;10(6):594-601 15624019 - Nat Genet. 2005 Jan;37(1):19-24 16651424 - Cancer Res. 2006 May 1;66(9):4715-24 16096426 - Anticancer Drugs. 2005 Sep;16(8):797-803 10922410 - J Natl Cancer Inst. 2000 Aug 2;92(15):1252-9 6577010 - J Cancer Res Clin Oncol. 1983;106 Suppl:21-4 17327929 - Acta Histochem Cytochem. 2006 Jul 1;39(3):95-100 11493700 - Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9666-70 7449206 - Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 16039868 - Crit Rev Oncol Hematol. 2005 Oct;56(1):47-60 15046615 - Biochem Soc Trans. 2004 Apr;32(Pt 2):393-6 15780592 - Curr Opin Cell Biol. 2005 Apr;17(2):158-66 10197603 - Cancer Res. 1999 Apr 1;59(7):1408-11 18972316 - Pathology. 2009 Feb;41(2):149-54 15623635 - Clin Cancer Res. 2004 Dec 15;10(24):8531-7 17440983 - Cancer. 2007 Jun 1;109 (11):2257-67 16002336 - Trends Mol Med. 2005 Aug;11(8):353-61 16467077 - Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89 16551370 - Int Semin Surg Oncol. 2006 Mar 21;3:7 17360108 - Cancer Lett. 2007 Aug 18;253(2):236-48 19836228 - Surg Oncol. 2011 Mar;20(1):13-9 16831079 - Expert Rev Anticancer Ther. 2006 Jul;6(7):1075-85 11953816 - Br J Cancer. 2002 Mar 18;86(6):864-9 16550606 - Int J Cancer. 2006 Aug 15;119(4):757-64 18652687 - BMC Genomics. 2008 Jul 24;9:348 16860938 - Cancer Treat Rev. 2006 Oct;32(6):423-36 16715128 - Oncogene. 2006 Nov 9;25(53):7029-40 |
References_xml | – volume: 25 start-page: 7029 year: 2006 end-page: 7040 ident: CR12 article-title: Rapamycin inhibits cell motility by suppression of mTOR mediated S6K1 and 4EBP1 pathways publication-title: Oncogene doi: 10.1038/sj.onc.1209691 – volume: 109 start-page: 2257 year: 2007 end-page: 2267 ident: CR17 article-title: Prognostic relevance of the mTOR pathway in renal cell carcinoma publication-title: Cancer doi: 10.1002/cncr.22677 – volume: 32 start-page: 423 year: 2006 end-page: 436 ident: CR1 article-title: Primary bone osteosarcoma in the pediatric age: state of the art publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2006.05.005 – volume: 17 start-page: 158 year: 2005 end-page: 166 ident: CR9 article-title: The expanding TOR signaling network publication-title: Curr Opin Cell Biol doi: 10.1016/j.ceb.2005.02.008 – volume: 10 start-page: 594 year: 2004 end-page: 601 ident: CR24 article-title: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways publication-title: Nat Med doi: 10.1038/nm1052 – volume: 153 start-page: 106 year: 1980 end-page: 120 ident: CR15 article-title: A system for the surgical staging of musculoskeletal sarcoma publication-title: Clin Orthop Relat Res – volume: 10 start-page: 8531 year: 2004 end-page: 8537 ident: CR18 article-title: Prognostic relevance of increased angiogenesis in osteosarcoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0969 – volume: 39 start-page: 95 year: 2006 end-page: 100 ident: CR6 article-title: Survivin as a prognostic factor for osteosarcoma patient publication-title: Acta Histochem Cytochem doi: 10.1267/ahc.06005 – volume: 253 start-page: 236 year: 2007 end-page: 248 ident: CR28 article-title: An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR publication-title: Cancer Lett doi: 10.1016/j.canlet.2007.01.026 – volume: 12 start-page: 679 year: 2006 end-page: 689 ident: CR21 article-title: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-1654 – volume: 294 start-page: 1942 year: 2001 end-page: 1945 ident: CR22 article-title: Phosphatidic acid-mediated mitogenic activation of mTOR signaling publication-title: Science doi: 10.1126/science.1066015 – volume: 86 start-page: 864 year: 2002 end-page: 869 ident: CR19 article-title: Increased pretherapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma publication-title: Br J Cancer doi: 10.1038/sj.bjc.6600201 – volume: 59 start-page: 1408 year: 1999 end-page: 1411 ident: CR11 article-title: Localization of PS6 K to chromosomal region 17q23 and determination of its amplification in breast cancer publication-title: Cancer Res – volume: 119 start-page: 757 year: 2006 end-page: 764 ident: CR27 article-title: Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells publication-title: Int J Cancer doi: 10.1002/ijc.21932 – volume: 92 start-page: 1252 year: 2000 end-page: 1259 ident: CR13 article-title: Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.15.1252 – volume: 32 start-page: 393 year: 2004 end-page: 396 ident: CR20 article-title: Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment publication-title: Biochem Soc Trans doi: 10.1042/BST0320393 – volume: 98 start-page: 9666 year: 2001 end-page: 9670 ident: CR26 article-title: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.171301998 – volume: 37 start-page: 19 year: 2005 end-page: 24 ident: CR7 article-title: Dysregulation of the TSC-mTOR pathway in human disease publication-title: Nat Genet doi: 10.1038/ng1494 – volume: 106 start-page: 21 issue: Suppl year: 1983 end-page: 24 ident: CR16 article-title: Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80 publication-title: J Cancer Res Clin Oncol doi: 10.1007/BF00625047 – volume: 41 start-page: 149 year: 2009 end-page: 54 ident: CR4 article-title: The expression of novel gene URG4 in osteosarcoma: correlation with patients’ prognosis publication-title: Pathology doi: 10.1080/00313020802436808 – volume: 56 start-page: 47 year: 2005 end-page: 60 ident: CR10 article-title: Rapamycin: an anti-cancer immunosuppressant? publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2004.09.009 – ident: CR5 – volume: 6 start-page: 1075 year: 2006 end-page: 1085 ident: CR2 article-title: Chemotherapy resistance in osteosarcoma: current challenges and future directions publication-title: Expert Rev Anticancer Ther doi: 10.1586/14737140.6.7.1075 – volume: 3 start-page: 7 year: 2006 end-page: 18 ident: CR3 article-title: Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? publication-title: Int Semin Surg Oncol doi: 10.1186/1477-7800-3-7 – volume: 9 start-page: 348 year: 2008 end-page: 359 ident: CR14 article-title: Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer publication-title: BMC Genomics doi: 10.1186/1471-2164-9-348 – volume: 66 start-page: 4715 year: 2006 end-page: 4724 ident: CR23 article-title: Survival signaling by notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-3830 – volume: 11 start-page: 353 year: 2005 end-page: 361 ident: CR8 article-title: An expanding role for mTOR in cancer publication-title: Trends Mol Med doi: 10.1016/j.molmed.2005.06.007 – volume: 16 start-page: 797 year: 2005 end-page: 803 ident: CR25 article-title: Mcleod. PI3 K/Akt/mTOR pathway as a target for cancer therapy publication-title: Anticancer Drugs doi: 10.1097/01.cad.0000173476.67239.3b – volume: 153 start-page: 106 year: 1980 ident: 9365_CR15 publication-title: Clin Orthop Relat Res doi: 10.1097/00003086-198011000-00013 – volume: 86 start-page: 864 year: 2002 ident: 9365_CR19 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6600201 – volume: 12 start-page: 679 year: 2006 ident: 9365_CR21 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-1654 – volume: 98 start-page: 9666 year: 2001 ident: 9365_CR26 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.171301998 – volume: 59 start-page: 1408 year: 1999 ident: 9365_CR11 publication-title: Cancer Res – volume: 10 start-page: 8531 year: 2004 ident: 9365_CR18 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0969 – volume: 25 start-page: 7029 year: 2006 ident: 9365_CR12 publication-title: Oncogene doi: 10.1038/sj.onc.1209691 – volume: 56 start-page: 47 year: 2005 ident: 9365_CR10 publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2004.09.009 – volume: 9 start-page: 348 year: 2008 ident: 9365_CR14 publication-title: BMC Genomics doi: 10.1186/1471-2164-9-348 – ident: 9365_CR5 doi: 10.1016/j.suronc.2009.09.002 – volume: 41 start-page: 149 year: 2009 ident: 9365_CR4 publication-title: Pathology doi: 10.1080/00313020802436808 – volume: 11 start-page: 353 year: 2005 ident: 9365_CR8 publication-title: Trends Mol Med doi: 10.1016/j.molmed.2005.06.007 – volume: 119 start-page: 757 year: 2006 ident: 9365_CR27 publication-title: Int J Cancer doi: 10.1002/ijc.21932 – volume: 109 start-page: 2257 year: 2007 ident: 9365_CR17 publication-title: Cancer doi: 10.1002/cncr.22677 – volume: 39 start-page: 95 year: 2006 ident: 9365_CR6 publication-title: Acta Histochem Cytochem doi: 10.1267/ahc.06005 – volume: 253 start-page: 236 year: 2007 ident: 9365_CR28 publication-title: Cancer Lett doi: 10.1016/j.canlet.2007.01.026 – volume: 32 start-page: 423 year: 2006 ident: 9365_CR1 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2006.05.005 – volume: 17 start-page: 158 year: 2005 ident: 9365_CR9 publication-title: Curr Opin Cell Biol doi: 10.1016/j.ceb.2005.02.008 – volume: 32 start-page: 393 year: 2004 ident: 9365_CR20 publication-title: Biochem Soc Trans doi: 10.1042/bst0320393 – volume: 66 start-page: 4715 year: 2006 ident: 9365_CR23 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-3830 – volume: 6 start-page: 1075 year: 2006 ident: 9365_CR2 publication-title: Expert Rev Anticancer Ther doi: 10.1586/14737140.6.7.1075 – volume: 92 start-page: 1252 year: 2000 ident: 9365_CR13 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.15.1252 – volume: 106 start-page: 21 issue: Suppl year: 1983 ident: 9365_CR16 publication-title: J Cancer Res Clin Oncol doi: 10.1007/BF00625047 – volume: 10 start-page: 594 year: 2004 ident: 9365_CR24 publication-title: Nat Med doi: 10.1038/nm1052 – volume: 294 start-page: 1942 year: 2001 ident: 9365_CR22 publication-title: Science doi: 10.1126/science.1066015 – volume: 3 start-page: 7 year: 2006 ident: 9365_CR3 publication-title: Int Semin Surg Oncol doi: 10.1186/1477-7800-3-7 – volume: 16 start-page: 797 year: 2005 ident: 9365_CR25 publication-title: Anticancer Drugs doi: 10.1097/01.cad.0000173476.67239.3b – volume: 37 start-page: 19 year: 2005 ident: 9365_CR7 publication-title: Nat Genet doi: 10.1038/ng1494 – reference: 16467077 - Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89 – reference: 10197603 - Cancer Res. 1999 Apr 1;59(7):1408-11 – reference: 17440983 - Cancer. 2007 Jun 1;109 (11):2257-67 – reference: 15156201 - Nat Med. 2004 Jun;10(6):594-601 – reference: 18972316 - Pathology. 2009 Feb;41(2):149-54 – reference: 16550606 - Int J Cancer. 2006 Aug 15;119(4):757-64 – reference: 17360108 - Cancer Lett. 2007 Aug 18;253(2):236-48 – reference: 15780592 - Curr Opin Cell Biol. 2005 Apr;17(2):158-66 – reference: 11493700 - Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9666-70 – reference: 16039868 - Crit Rev Oncol Hematol. 2005 Oct;56(1):47-60 – reference: 15623635 - Clin Cancer Res. 2004 Dec 15;10(24):8531-7 – reference: 16002336 - Trends Mol Med. 2005 Aug;11(8):353-61 – reference: 16715128 - Oncogene. 2006 Nov 9;25(53):7029-40 – reference: 18652687 - BMC Genomics. 2008 Jul 24;9:348 – reference: 19836228 - Surg Oncol. 2011 Mar;20(1):13-9 – reference: 16551370 - Int Semin Surg Oncol. 2006 Mar 21;3:7 – reference: 16860938 - Cancer Treat Rev. 2006 Oct;32(6):423-36 – reference: 16096426 - Anticancer Drugs. 2005 Sep;16(8):797-803 – reference: 11953816 - Br J Cancer. 2002 Mar 18;86(6):864-9 – reference: 7449206 - Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 – reference: 15624019 - Nat Genet. 2005 Jan;37(1):19-24 – reference: 10922410 - J Natl Cancer Inst. 2000 Aug 2;92(15):1252-9 – reference: 11729323 - Science. 2001 Nov 30;294(5548):1942-5 – reference: 15046615 - Biochem Soc Trans. 2004 Apr;32(Pt 2):393-6 – reference: 16651424 - Cancer Res. 2006 May 1;66(9):4715-24 – reference: 16831079 - Expert Rev Anticancer Ther. 2006 Jul;6(7):1075-85 – reference: 6577010 - J Cancer Res Clin Oncol. 1983;106 Suppl:21-4 – reference: 17327929 - Acta Histochem Cytochem. 2006 Jul 1;39(3):95-100 |
SSID | ssj0021529 |
Score | 2.1438441 |
Snippet | The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells’ survival and proliferation. However, its roles in osteosarcoma,... The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma,... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1239 |
SubjectTerms | Adolescent Adult Antibodies Bone Neoplasms - metabolism Bone Neoplasms - secondary Cancer Cell proliferation Cell survival Child Child, Preschool Disease Progression Female Hematology Humans Immunoenzyme Techniques Immunohistochemistry Internal Medicine Male Medicine Medicine & Public Health Metastases Middle Aged Multivariate analysis Neoplasm Staging Oncology Original Paper Osteosarcoma Osteosarcoma - metabolism Osteosarcoma - pathology Pathology Prognosis Regression analysis Ribosomal Protein S6 Kinases, 70-kDa - metabolism Sarcoma Signal Transduction Survival Rate TOR protein TOR Serine-Threonine Kinases - metabolism Young Adult |
SummonAdditionalLinks | – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEB58XLyI4qu-iCAISrHbpk1yEhFFFBV8wN5KXhVB29VWZP-9mbTbRUQvvSSlYWaSmelMvg9g3xmBjV0kERrGdEgVj0KVGuseVslkkFrq2RpubrPLJ3o1TIddb07dtVVOzkR_UJtK4z_yY4GZCuLbnYzeQySNwuJqx6AxC_OIXIYdXWw4zbecaxI-30pZ6Px8X9T0N-eQOTzEyoDAPq_xT7f0K9b8VSf17udiCRa7uJGctopehhlbrsDz2-Pd_fGIRQ_ZNXl4ecYZDTof02LCEuQb_pJj4hvSkdnK1qSpCF7sqGpn4tWbJL5Dq0XnILI0pENarQ_8SFnVL_UqPF2cP55dhh1zQqhduts4t6ONkLRQMdUsiXViXBxotSiSqJCpHKQslkJmKlO8UJG1SZwYKng2yLSNBOfJGsyVVWk3gHCeMeuSMsYGirpgR0QmlrGMlC44LaQJIJoILtcdrDiyW7zmU0BklHXuZJ2jrPNxAIf9K6MWU-O_yVsTbeTd9qrz3hgC2OtH3b7AYocsbfVZY2U9cU7A5ZMBkD_mcMSzQ0i6ANZbPU_XI5DpkNEAjiaKn37-z8Vu_rvYLViI-2aYbZhrPj7tjgtpGrXrDfcb_-Ty7g priority: 102 providerName: ProQuest |
Title | mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis |
URI | https://link.springer.com/article/10.1007/s12032-009-9365-y https://www.ncbi.nlm.nih.gov/pubmed/19936974 https://www.proquest.com/docview/921100249 https://www.proquest.com/docview/1093467289 https://www.proquest.com/docview/812135518 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwEB7RVkJcEP-khZWROIEiso4T28cFbamoWlDblZZTZDtOtRJNKpKq2huvwevxJMzkb4VKkbgkh0wSazzOzJcZfwPwGo3Ac4wkwlxKFwqrotAmuceDtyaeJl603RqOjtODhfi0TJb9Pu56qHYfUpLtl3qz2Y2afYf0M19TadZ6C3YSgu5oxAs-G1EWOiTdoqxEhujdx1Tm3x7xpzO6EWHeyI62Tmf_Adzvo0U266b3Idzx5SO4e9Tnwx_D6uLs88m7SxmdpofsdHVOwg15n7wjhWXUcPjarFlbkU6trXzNmorRzo6qRhuvLgxrS7Q6eg5mypz1VKv1rx8_22tlVa_qJ7DYn599OAj75gmhQ8TboOdxuTaisFw4GXMX5xgKeqeLOCpMYqaJ5Eab1KZWFTbyPuZxLrRKp6nzkVYqfgrbZVX658CUSqVHXCbl1AqMd3SUc8NNZF2hRGHyAKJBi5nrmcWpwcW3bMOJTIrPUPEZKT5bB_BmvOWyo9X4l_DeMDVZv8LqTBNyJb7DAF6NV3FpUL7DlL66qim5HqMfQEgZALtFRhGlHbHSBfCsm_TNeDQ1O5QigLeDFWxef-tgd_9Leg_u8bE-5gVsN9-v_EuMcho7gS25lBPYmX38ejjH8_v58ZeTSWvrvwHNp_md |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9RADLbK9gAXBOIVWmCQQEigqNnJJJMcEOLRasu2C2q3Um9hXqkq0WRLUlX7o_iP2HmtUNXeesklk2Rke8Z27Pk-gDdoBI5jJOFbKY0vdBL4OrIOL06rcBw50bA17M_iyZH4fhwdr8Hf_iwMtVX2e2KzUdvS0D_yrZQyFcK3-7Q494k0ioqrPYNGaxVTt7zEjK36uPsN1fuW853t-deJ35EK-AYzwRp3ZGNTJXLNhZEhN6HFEMmZNA-DXEVqHEmuUhXrWCe5DpwLeWhFmsTj2LggTZIQ33sH1kWImcwI1r9sz34eDBkeOsO0yfAi6WNkMZRRm7N6xFXuUy0ipc6y5f-O8Ep0e6Uy2zi8nQdwv4tU2efWtB7CmisewcnZ_MfB1kIGh_GUHZ6e0Iia3J1tUWgZMRxfqiVrWuCJS8tVrC4ZHSUpKxRfeaZY0xPW4oEwVVjWYbtW75o7RVmdVo_h6FbE-gRGRVm4Z8CSJJYO00Apx1pgeJUGliuuAm3yROTKehD0gstMB2ROfBq_sxUEM8k6Q1lnJOts6cH74ZFFi-Jx0-CNXhtZt6CrbDA_D14Pd3ElUnlFFa68qKiWH6LbwQzWA3bNmIQQ9AgEz4OnrZ5X80mJW1EKDz70il99_trJPr9xsq_g7mS-v5ft7c6mG3CPD604mzCq_1y4FxhQ1fplZ8YMft32yvkHG-sxmA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9VAEB5qBfFFFG-xXlZQBCWcZHPZ7IOU0npoPVrFtnDe0r2lFGxyNCnl_DT_XWdyO0hp3_qSl2ySZXZmZyYz-30A71AJHMdIwrdCGD_WWeDrxDq8OK2iMHFxy9bwfT_dPYq_zpP5GvwbzsJQW-WwJ7Ybta0M_SOfSMpUCN9uUvRdET93ppuLPz4RSFGhdWDT6DRk5pYXmL3Vn_d2cKnfcz79cri96_cEA77BrLDB3dlYqeJC89iIiJvIYrjkjCyioFCJChPBlVSpTnVW6MC5iEc2llkapsYFMssifO8duCuiJCQTE_NVroduUba5XiJ8jDHGgmp7ao9Yy32qSkjqMVv-7xKvxLlXarSt65s-hAd9zMq2OiV7BGuufAwnZ4c_fk0WIjhIZ-zg9IRGNOT4bIdHy4jr-EItWdsMT6xarmZNxehQSVWj8KozxdrusA4ZhKnSsh7ltf7Q3imr-rR-Ake3ItSnsF5WpXsOLMtS4TAhFCLUMQZaMrBccRVoU2RxoawHwSC43PSQ5sSs8TtfgTGTrHOUdU6yzpcefBwfWXR4HjcN3hhWI-9Nu85HRfTg7XgXbZIKLap01XlNVf0IHRDmsh6wa8ZkhKVHcHgePOvWeTUfSSyLIvbg07Dwq89fO9kXN072DdxDe8m_7e3PNuA-H3tyXsJ68_fcvcLIqtGvWx1mcHzbRnMJEUA0aA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=mTOR%2Fp70S6K+Signal+transduction+pathway+contributes+to+osteosarcoma+progression+and+patients%E2%80%99+prognosis&rft.jtitle=Medical+oncology+%28Northwood%2C+London%2C+England%29&rft.au=Zhou%2C+Quan&rft.au=Deng%2C+Zhansheng&rft.au=Zhu%2C+Yong&rft.au=Long%2C+Haitao&rft.date=2010-12-01&rft.issn=1357-0560&rft.eissn=1559-131X&rft.volume=27&rft.issue=4&rft.spage=1239&rft.epage=1245&rft_id=info:doi/10.1007%2Fs12032-009-9365-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s12032_009_9365_y |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1357-0560&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1357-0560&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1357-0560&client=summon |